These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 9267669)

  • 1. The significance of tumor contamination in the bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic support.
    Vredenburgh JJ; Silva O; Broadwater G; Berry D; DeSombre K; Tyer C; Petros WP; Peters WP; Bast RC
    Biol Blood Marrow Transplant; 1997 Jun; 3(2):91-7. PubMed ID: 9267669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13.
    Peters WP; Rosner GL; Vredenburgh JJ; Shpall EJ; Crump M; Richardson PG; Schuster MW; Marks LB; Cirrincione C; Norton L; Henderson IC; Schilsky RL; Hurd DD
    J Clin Oncol; 2005 Apr; 23(10):2191-200. PubMed ID: 15767638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy.
    Cheng YC; Rondón G; Yang Y; Smith TL; Gajewski JL; Donato ML; Shpall EJ; Jones R; Hortobagyi GN; Champlin RE; Ueno NT
    Biol Blood Marrow Transplant; 2004 Nov; 10(11):794-804. PubMed ID: 15505610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancer.
    Hohaus S; Funk L; Martin S; Schlenk RF; Abdallah A; Hahn U; Egerer G; Goldschmidt H; Schneeweiss A; Fersis N; Kaul S; Wallwiener D; Bastert G; Haas R
    Br J Cancer; 1999 Mar; 79(9-10):1500-7. PubMed ID: 10188897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer.
    Tallman MS; Gray R; Robert NJ; LeMaistre CF; Osborne CK; Vaughan WP; Gradishar WJ; Pisansky TM; Fetting J; Paietta E; Lazarus HM
    N Engl J Med; 2003 Jul; 349(1):17-26. PubMed ID: 12840088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, comparative study of high-dose (with autologous bone marrow support) versus low-dose cyclophosphamide, cisplatin, and carmustine as consolidation to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for patients with operable stage II or III breast cancer involving 10 or more axillary lymph nodes (CALGB Protocol 9082). Cancer and Leukemia Group B.
    Hurd DD; Peters WP
    J Natl Cancer Inst Monogr; 1995; (19):41-4. PubMed ID: 7577204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose chemotherapy with autologous stem cell rescue in women with metastatic breast cancer with involved bone marrow: a role for peripheral blood progenitor transplant.
    Myers SE; Mick R; Williams SF
    Bone Marrow Transplant; 1994 Apr; 13(4):449-54. PubMed ID: 8019470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer.
    Rodenhuis S; Bontenbal M; Beex LV; Wagstaff J; Richel DJ; Nooij MA; Voest EE; Hupperets P; van Tinteren H; Peterse HL; TenVergert EM; de Vries EG;
    N Engl J Med; 2003 Jul; 349(1):7-16. PubMed ID: 12840087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Her2/neu overexpression is associated with treatment failure in women with high-risk stage II and stage IIIA breast cancer (>10 involved lymph nodes) treated with high-dose chemotherapy and autologous hematopoietic progenitor cell support following standard-dose adjuvant chemotherapy.
    Bitran JD; Samuels B; Trujillo Y; Klein L; Schroeder L; Martinec J
    Clin Cancer Res; 1996 Sep; 2(9):1509-13. PubMed ID: 9816327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose chemotherapy with autologous bone marrow support as consolidation after standard-dose adjuvant therapy in primary breast cancer patients with seven or more involved axillary lymph nodes.
    Lalisang RI; Hupperets PS; ten Haaft MA; Jansen RL; Schouten HC
    Bone Marrow Transplant; 1998 Feb; 21(3):243-7. PubMed ID: 9489646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of the detection of tumour cells in peripheral blood stem cell collections in stage II and III breast cancer patients treated with high-dose therapy.
    Patriarca F; Sacco C; Sperotto A; Geromin A; Damiani D; Fili C; Cerno M; Clochiatti L; Cartei G; Fanin R
    Bone Marrow Transplant; 2003 May; 31(9):789-94. PubMed ID: 12732886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of the immunocytochemical detection of contaminating tumor cells (CTC) in apheresis products of patients with high-risk breast cancer treated with high-dose chemotherapy and stem cell transplantation.
    Solano C; Badia B; Lluch A; Marugan I; Benet I; Arbona C; Prosper F; García-Conde J
    Bone Marrow Transplant; 2001 Feb; 27(3):287-93. PubMed ID: 11277176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poor outcome of patients with resectable breast cancer receiving adjuvant high-dose sequential chemotherapy following preoperative treatment.
    Zambelli A; Da Prada GA; Pedrazzoli P; Ponchio L; Robustelli della Cuna G
    Anticancer Res; 1999; 19(3B):2373-6. PubMed ID: 10472359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
    Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
    J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor cell contamination of peripheral blood stem cell transplants and bone marrow in high-risk breast cancer patients.
    Schulze R; Schulze M; Wischnik A; Ehnle S; Doukas K; Behr W; Ehret W; Schlimok G
    Bone Marrow Transplant; 1997 Jun; 19(12):1223-8. PubMed ID: 9208116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years.
    Hanrahan EO; Broglio K; Frye D; Buzdar AU; Theriault RL; Valero V; Booser DJ; Singletary SE; Strom EA; Gajewski JL; Champlin RE; Hortobagyi GN
    Cancer; 2006 Jun; 106(11):2327-36. PubMed ID: 16639731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of a pilot study of 40 patients using high-dose therapy with hematopoietic rescue after standard-dose adjuvant therapy for high-risk breast cancer.
    Tomás JF; Pérez-Carrión R; Escudero A; López-Lorenzo JL; López-Pascual J; Fernández-Rañada JM
    Bone Marrow Transplant; 1997 Feb; 19(4):331-6. PubMed ID: 9051242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant treatment of high-risk stage II breast cancer with doxorubicin followed by high-dose chemotherapy and autologous stem-cell transplantation: a single-institution experience with 132 consecutive patients.
    Stemmer SM; Hardan I; Raz H; Adamou AK; Inbar M; Gottfried M; Merrick Y; Cohen Y; Sulkes A; Ben-Baruch N; Pfeffer RP; Brenner HJ; Rizel S
    Bone Marrow Transplant; 2003 Apr; 31(8):655-61. PubMed ID: 12692605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.
    Kanteti R; Miller K; McCann J; Roitman D; Morelli J; Hurley C; Berkman E; Schenkein D
    Bone Marrow Transplant; 1999 Sep; 24(5):473-81. PubMed ID: 10482930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.